Coagulation factor II (F2)

Coagulation factor II, commonly known as thrombin in its active form, is a critical serine protease in the blood coagulation cascade (StatPearls, 2023). It is generated from its zymogen precursor, prothrombin, by the action of the prothrombinase complex during the initiation and amplification phases of clot formation (UniProt P00734). The primary biological function of thrombin is the conversion of soluble fibrinogen into insoluble fibrin monomers, which polymerize to form the structural basis of a blood clot (PubMed, PMID: 15507601). Thrombin also activates factor XIII to factor XIIIa, which cross-links fibrin polymers to provide mechanical stability to the thrombus (NIH, 2022). Beyond its role in fibrin formation, thrombin is a potent activator of platelets through the cleavage of protease-activated receptors (PARs) on the platelet surface (NCBI, 2023). In clinical pathology, dysregulated thrombin activity is a central driver of arterial and venous thrombosis, leading to conditions such as myocardial infarction, stroke, and deep vein thrombosis (PubChem, 2024). Thrombin is a major therapeutic target for anticoagulants, including direct thrombin inhibitors like dabigatran and indirect inhibitors like heparin, which are used to prevent and treat thromboembolic events (StatPearls, 2023). The therapeutic use of thrombin inhibitors requires careful monitoring due to the significant risk of major bleeding complications, such as intracranial or gastrointestinal hemorrhage (NIH, 2023).

Other names

ThrombinProthrombinActivated factor IIFIIaFibrinogenase

Direct or indirect inhibition of the proteolytic activity of thrombin, preventing the conversion of fibrinogen to fibrin and the activation of platelets.